Transcode Therapeutics Inc (RNAZ) - Total Liabilities
Based on the latest financial reports, Transcode Therapeutics Inc (RNAZ) has total liabilities worth $152.06 Million USD as of March 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Transcode Therapeutics Inc - Total Liabilities Trend (2018–2025)
This chart illustrates how Transcode Therapeutics Inc's total liabilities have evolved over time, based on quarterly financial data. See Transcode Therapeutics Inc short-term liquidity ratio to evaluate short-term liquidity relative to the company's equity base.
Transcode Therapeutics Inc Competitors by Total Liabilities
The table below lists competitors of Transcode Therapeutics Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
TENET FINTECH GROUP INC.
F:P0T
|
Germany | €29.27 Million |
|
Dermata Therapeutics Inc
NASDAQ:DRMA
|
USA | $1.64 Million |
|
Fabric.AI, Inc.
NASDAQ:FABC
|
USA | $1.70 Million |
|
LUPAKA GOLD CORP.
F:LQPA
|
Germany | €408.58K |
|
Akash Infra-Projects Limited
NSE:AKASH
|
India | Rs1.34 Billion |
|
Halfords Group PLC
LSE:HFD
|
UK | GBX675.70 Million |
|
IMMO BLOCKCHAIN EO 1
F:QT5
|
Germany | €7.02 Million |
|
Hapbee Technologies Inc
V:HAPB
|
Canada | CA$3.86 Million |
Liability Composition Analysis (2018–2025)
This chart breaks down Transcode Therapeutics Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see RNAZ market cap overview.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 6.29 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 14.71 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.94 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Transcode Therapeutics Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Transcode Therapeutics Inc (2018–2025)
The table below shows the annual total liabilities of Transcode Therapeutics Inc from 2018 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $152.06 Million | +1532.77% |
| 2024-12-31 | $9.31 Million | +163.91% |
| 2023-12-31 | $3.53 Million | -18.83% |
| 2022-12-31 | $4.35 Million | +71.55% |
| 2021-12-31 | $2.53 Million | -43.23% |
| 2020-12-31 | $4.46 Million | +239.63% |
| 2019-12-31 | $1.31 Million | +82.89% |
| 2018-12-31 | $718.61K | -- |
About Transcode Therapeutics Inc
TransCode Therapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing drugs and diagnostics for treating and identifying cancer. The company's lead therapeutic candidate comprises TTX-MC138 that targets microRNA-10b, a master regulator of metastatic cell viability in various cancers comprising breast, pancreatic, ovarian, colon cancer, glioblastomas, and others. Its… Read more